La­va Ther­a­peu­tics makes cuts to its head­count

La­va Ther­a­peu­tics said Tues­day that it cut 36% of its staff af­ter the biotech stopped all work on a ther­a­py look­ing to go af­ter CD1d-ex­press­ing hema­to­log­i­cal tu­mors.

The com­pa­ny em­ployed 69 full-time em­ploy­ees as of Dec. 31, 2022. It told in­vestors this week that its cash run­way now ex­tends in­to 2026, and it’s pri­or­i­tiz­ing its work on LA­VA-1207, a metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer treat­ment in Phase I/IIa. La­va al­so ex­pects more da­ta on the drug with­in the next 12 months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.